Brain cancer patients get continued access to promising combo therapy in new study

NCT ID NCT07569042

First seen May 07, 2026 · Last updated May 07, 2026

Summary

This study offers continued access to an experimental drug (NBM-BMX) combined with standard chemotherapy (temozolomide) for people with newly diagnosed glioblastoma, a serious brain cancer. Participants must have completed a previous study of this combination. The goal is to monitor long-term safety and see how well the treatment controls the cancer over time. About 15 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF BRAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, 807, Taiwan

    Contact Phone: •••-•••-••••

  • Linkou Chang-Gung Memorial Hospital

    RECRUITING

    Taoyuan City, 333, Taiwan

    Contact Phone: •••-•••-••••

  • Taichung Veterans General Hospital

    NOT_YET_RECRUITING

    Taichung, 407, Taiwan

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.